Low-Grade Serous Ovarian Cancer — Trials

Low-Grade Serous Ovarian Cancer — Trials · CancerIndex

Clinical trials

Registered studies

6 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 3
Ph III recruiting: 1
Growth YoY: —
Industry share: 60%
Top sponsor: Verastem, Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01849874	A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer	terminated	Phase 3	341	PfizerINDUSTRY	19	Oct 30, 2023	clinicaltrials

Data updated 23 days agoSource updated Oct 30, 2023source: clinicaltrials